Harris LF - Search Results

1

Point of care diagnostics: status and future.

Gubala V, Harris LF, Ricco AJ, Tan MX, Williams DE. Gubala V, et al. Among authors: harris lf. Anal Chem. 2012 Jan 17;84(2):487-515. doi: 10.1021/ac2030199. Epub 2011 Dec 21. Anal Chem. 2012. PMID: 22221172 Review. No abstract available.

2

A microfluidic anti-Factor Xa assay device for point of care monitoring of anticoagulation therapy.

Harris LF, Rainey P, Castro-López V, O'Donnell JS, Killard AJ. Harris LF, et al. Analyst. 2013 Sep 7;138(17):4769-76. doi: 10.1039/c3an00401e. Epub 2013 May 13. Analyst. 2013. PMID: 23666610

3

Comparative study of Factor Xa fluorogenic substrates and their influence on the quantification of LMWHs.

Castro-López V, Harris LF, O'Donnell JS, Killard AJ. Castro-López V, et al. Among authors: harris lf. Anal Bioanal Chem. 2011 Jan;399(2):691-700. doi: 10.1007/s00216-010-4314-3. Epub 2010 Oct 24. Anal Bioanal Chem. 2011. PMID: 20972772

4

Evaluation of activated partial thromboplastin time (aPTT) reagents for application in biomedical diagnostic device development.

Dudek MM, Harris LF, Killard AJ. Dudek MM, et al. Among authors: harris lf. Int J Lab Hematol. 2011 Jun;33(3):272-80. doi: 10.1111/j.1751-553X.2010.01283.x. Epub 2010 Dec 1. Int J Lab Hematol. 2011. PMID: 21118388

5

Microfluidics in Haemostasis: A Review.

Jigar Panchal H, Kent NJ, Knox AJS, Harris LF. Jigar Panchal H, et al. Among authors: harris lf. Molecules. 2020 Feb 14;25(4):833. doi: 10.3390/molecules25040833. Molecules. 2020. PMID: 32075008 Free PMC article. Review.

6

Comparison of the anticoagulant response of a novel fluorogenic anti-FXa assay with two commercial anti-FXa chromogenic assays.

Harris LF, O'Brien A, Castro-López V, O'Donnell JS, Killard AJ. Harris LF, et al. Thromb Res. 2011 Dec;128(6):e166-70. doi: 10.1016/j.thromres.2011.08.002. Epub 2011 Aug 27. Thromb Res. 2011. PMID: 21872908

7

Comparison of a fluorogenic anti-FXa assay with a central laboratory chromogenic anti-FXa assay for measuring LMWH activity in patient plasmas.

Harris LF, Castro-López V, Jenkins PV, O'Donnell JS, Killard AJ. Harris LF, et al. Thromb Res. 2011 Dec;128(6):e125-9. doi: 10.1016/j.thromres.2011.07.011. Epub 2011 Aug 7. Thromb Res. 2011. PMID: 21824646

8

Effects of four commercially available factor Xa proteins on the fluorogenic anti-factor Xa assay when monitoring unfractionated heparin.

Castro-López V, Murray B, Harris LF, O'Donnell JS, Killard AJ. Castro-López V, et al. Among authors: harris lf. Blood Coagul Fibrinolysis. 2012 Jan;23(1):98-103. doi: 10.1097/MBC.0b013e32834ddf4d. Blood Coagul Fibrinolysis. 2012. PMID: 22089943

9

Development of a fluorescent anti-factor Xa assay to monitor unfractionated and low molecular weight heparins.

Harris LF, Castro-López V, Hammadi N, O'Donnell JS, Killard AJ. Harris LF, et al. Talanta. 2010 Jun 15;81(4-5):1725-30. doi: 10.1016/j.talanta.2010.03.030. Epub 2010 Mar 25. Talanta. 2010. PMID: 20441964

10

Quantification of unfractionated heparin in human plasma and whole blood by means of novel fluorogenic anti-FXa assays.

Castro-López V, Harris LF, O'Donnell JS, Killard AJ. Castro-López V, et al. Among authors: harris lf. J Pharm Biomed Anal. 2011 Dec 15;56(5):992-7. doi: 10.1016/j.jpba.2011.07.025. Epub 2011 Jul 28. J Pharm Biomed Anal. 2011. PMID: 21852056

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

98 results

Search Page